BECLAZONE

This brand name is authorized in Cyprus, Estonia, Hong Kong SAR China, Ireland, New Zealand.

Active ingredients

The drug BECLAZONE contains one active pharmaceutical ingredient (API):

1	Beclometasone UNII 5B307S63B2 - BECLOMETHASONE DIPROPIONATE
	Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity.
	Read more about Beclometasone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BECLAZONE 250mg Pressurised inhalation, solution	MPI, EU: SmPC	Υπουργείο Υγείας (CY)
BECLAZONE 100mg Pressurised inhalation, solution	MPI, EU: SmPC	Υπουργείο Υγείας (CY)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03BA01	Beclometasone	R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BA Glucocorticoids
Discover more medicines within R03BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1689587
HK	Department of Health Drug Office	43841, 43844
IE	Health Products Regulatory Authority	13926, 13952, 13967, 13978, 14091, 14111, 14122
NZ	Medicines and Medical Devices Safety Authority	11203, 11204, 11205